Social entrepreneurship network Ashoka and pharmaceutical company, Boehringer Ingelheim have both launched Making More Health (MMH), an 11-month accelerator programme for African founders.

The structured accelerator will bring together the best experience in social innovation and global healthcare to improve healthcare access for people, animals and their communities around the globe.

Participants will be provided with tailored access to expertise and capacity building to unlock their next phase of growth. A unique feature of the programme is its co-creation approach, which involves entrepreneurs working with Boehringer Ingelheim employees to collaboratively design and implement relevant interventions.

Benefits

  • Training (both virtual and in-person) on business growth and scaling strategies, investor engagement and pitching, tailored to the strategic needs of your organization.
  • Access to technical expertise (in-person) in finance, strategy, operations, information technology, marketing and social investing among others to help you address strategic capacity gaps specific to your organization.
  • Access to strategic networks including social investors, leading social entrepreneurs in the healthcare space and executive team members from Boehringer Ingelheim and Ashoka.
  • Funding of up to Euros 50k in cash plus additional in-kind expertise valued at Euros 100k.
    Investor engagement support including preparation of investor engagement materials and facilitated access to investors.
  • At the end of the accelerator, social entrepreneurs with successful interventions will have the opportunity to present their solutions to Boehringer Ingelheim’s leadership team as well as social investors to attract further investment

Eligibility

  • A fully registered legal entity that is at least two years old.
  • Post revenue with a product, customers and sales.
  • Established with an office, team, basic systems and processes in place.
  • Operating in Kenya, Ghana or Nigeria.
  • Open to working with a pharmaceutical company such as Boehringer Ingelheim in a co-creation approach.
  • Capacity to dedicate a full-time resource(s) to execute MMH Accelerator activities.
  • Potential to create shared-value through co-creation
  • Disruptive potential of innovation
  • Strategic fit for Boehringer Ingelheim
  • Late stage startups (at least two years old) in human health (non-communicable diseases) or animal health.

Application

Applications are open on the website until Friday,  February 15, 2019, with the programme beginning in April 2019.